Harvard Bioscience Inc (HBIO) Stock Analysis

Harvard Bioscience Inc (HBIO) is a publicly traded company in the HEALTHCARE sector. It trades at $6.46, carries a market capitalization of $28.87M. This page summarizes the public market data, fundamentals, and frequently asked questions for HBIO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL INSTRUMENTS & SUPPLIES

Exchange: NASDAQ

Key Metrics

• Price: $6.46
• Market Cap: $28.87M
• EPS: $-2.15
• 52-Week High: $9.40
• 52-Week Low: $3.70

Market Sentiment

Harvard Bioscience Inc currently has a Bullish sentiment score of 0.32.

About Harvard Bioscience Inc

Harvard Bioscience, Inc. is a leading global provider of innovative technologies and services that support fundamental research and drug development, focusing on preclinical testing and discovery. Headquartered in Holliston, Massachusetts, the company specializes in creating sophisticated instruments and apparatus that facilitate scientific exploration and enhance the efficiency of research processes across various biomedical disciplines. With a commitment to advancing life sciences, Harvard ...

GNG Research Analysis

GNG Research scores Harvard Bioscience Inc (HBIO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for HBIO.

Frequently Asked Questions

Does HBIO pay dividends?

Harvard Bioscience Inc (HBIO) does not currently pay a regular dividend.

What is HBIO's market cap?

Harvard Bioscience Inc (HBIO) has a market capitalization of $28.87M with a current stock price of $6.46.